RAPT Therapeutics, Inc. (RAPT)

Mar 3, 2026 - RAPT was delisted (reason: acquired by GSK)

58.02

0.00 (0.00%)

Inactive · Last trade price on Mar 2, 2026

RAPT Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Income	-105.64	-129.87	-116.8	-83.84	-69.2	-52.89
Depreciation & Amortization	0.97	1.2	1.22	1.05	1	1.12
Stock-Based Compensation	18.8	19.94	17.09	11.26	9.95	8.69
Other Adjustments	-0.57	-0.48	-4.06	2.09	1.53	0.25
Changes in Accounts Payable	3.33	-8.46	7.34	3.71	0.93	2.39
Changes in Unearned Revenue	-	-	-	-1.53	-3.43	0.96
Changes in Other Operating Activities	-20.98	34.37	-1.84	-3.52	-1.8	-1.01
Operating Cash Flow	-86.58	-83.3	-97.05	-70.77	-61.03	-40.49
Operating Cash Flow Growth	-	-	-	-	-	-

Investing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Capital Expenditures	-0.08	-0.12	-1.13	-0.85	-0.76	-0.4
Purchases of Investments	-217.2	-82.22	-161.5	-190.86	-164.98	-139.33
Proceeds from Sale of Investments	160.58	135.04	266.76	146.21	84.39	52.3
Investing Cash Flow	-56.7	52.7	104.13	-45.49	-81.35	-87.44

Financing Activities

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Issuance of Common Stock	0.26	152.85	1.45	131.18	141.48	75.46
Net Common Stock Issued (Repurchased)	0.26	152.85	1.45	131.18	141.48	75.46
Financing Cash Flow	143.31	152.85	1.45	131.18	141.48	75.46

Net Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Net Cash Flow	0.03	122.26	8.53	14.92	-0.89	-52.47

Free Cash Flow

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Free Cash Flow	-86.66	-83.42	-98.17	-71.62	-61.78	-40.89
Free Cash Flow Growth	-	-	-	-	-	-
FCF Margin	-	-	-	-4689.98%	-1620.27%	-810.97%
Free Cash Flow Per Share	-4.00	-16.37	-20.49	-17.61	-18.04	-13.55
Levered Free Cash Flow	-104.9	-102.88	-111.21	-84.97	-73.26	-49.82
Unlevered Free Cash Flow	-111.9	-109.11	-121.47	-86.93	-73.27	-51.16

SEC Filings: 10-K · 10-Q